FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2279131920> ?p ?o ?g. }

• W2279131920 abstract "ABSTRACT Background Less than 15% of patients (pts) receiving pre-operative chemoradiation (CRT) for rectal cancer have a complete pathological response (pCR). We tested the hypothesis that the addition of cediranib (a VEGFR TKI) or selumetinib (a MEK inhibitor), in combination with CRT, increases the proportion of complete responders. A translational protocol was also developed to study potential predictive biomarkers. Methods This hypothesis was evaluated in a dual phase I design. The drugs are evaluated in parallel in an intertwined design: once a cohort of pts on cediranib completed treatment and during the toxicity assessment period, another cohort of pts was commenced on selumetinib at the next dose level. Alternating cohorts maximised the efficacy of their evaluation. The analysis here is for cediranib only. Pts received CRT (45Gy in 25#, capecitabine 825 mg/m2 twice daily for 35 days) in three cohorts with cediranib: 15 mg, 20 mg and 30 mg/once daily (OD). Dose escalation was done upon fulfilment of the safety criteria outlined in the protocol. Cediranib was commenced 10 days prior to the start of CRT and continued throughout. Pts were followed up until and then after surgery. Safety, RECIST and pathological data were collected. In addition, blood, tissue and DCE-MRIs were obtained at baseline, post-monotherapy, throughout and post CRT for the study of candidate biomarkers. Results 15 mg cohort: 3 pts were recruited. 2 pts had a pCR and the 3rd pt had a clinical complete response (cCR) not requiring surgery. 20 mg cohort: 3 pts were treated. 1 had a cCR and ypT3N0 on resection. The other 2 had partial responses on MRI with ypT3N0 and ypT3N2 pathologically. 30 mg cohort: 3 pts were recruited at this dose level. Two pts had a cCR and the other one is waiting restaging. There was one DLT in this cohort (Grade III lethargy). This cohort will be expanded to a maximum n = 6. As yet, all pts have had R0 resections and completed all planned treatment (except pt with DLT who did not complete capecitabine). cCR pts remain disease free and have not had surgery. Conclusions The addition of cediranib to pre-operative CRT is a well tolerated regimen. All pts have responded with 5 out of 8 evaluable pts (62.5%) having either a pCR (n = 2) or cCR (n = 3). Updated clinical data, proposed optimal dose and translational data will be available for presentation at the meeting. Disclosure F.E. Marti Marti: Dr Marti's research fellowship is funded in equal parts by Cancer Research UK and Astra Zeneca. O. Ataman: Dr Ataman is an Astra Zeneca employee. G.C. Jayson: AZ advisory boards and research funding. M.P. Saunders: I have previously been a paid advisor on an AZ trial with AZD2171 (Horizon II). However, I have no conflicts on the use of this agent in the DREAMtherapy trial. All other authors have declared no conflicts of interest." @default.
• W2279131920 created "2016-06-24" @default.
• W2279131920 creator A5010422795 @default.
• W2279131920 creator A5016625039 @default.
• W2279131920 creator A5027021672 @default.
• W2279131920 creator A5027556665 @default.
• W2279131920 creator A5037610017 @default.
• W2279131920 creator A5039337111 @default.
• W2279131920 creator A5040081800 @default.
• W2279131920 creator A5048397234 @default.
• W2279131920 creator A5055743450 @default.
• W2279131920 creator A5067706688 @default.
• W2279131920 date "2012-09-01" @default.
• W2279131920 modified "2023-10-01" @default.
• W2279131920 title "First Results from the Phase I Dual Rectal Angiogenesis Mek Inhibition Radiotherapy (DreamTherapy) Trial in Locally Advanced Rectal Cancer" @default.
• W2279131920 doi "https://doi.org/10.1016/s0923-7534(20)33224-5" @default.
• W2279131920 hasPublicationYear "2012" @default.
• W2279131920 type Work @default.
• W2279131920 sameAs 2279131920 @default.
• W2279131920 citedByCount "0" @default.
• W2279131920 crossrefType "journal-article" @default.
• W2279131920 hasAuthorship W2279131920A5010422795 @default.
• W2279131920 hasAuthorship W2279131920A5016625039 @default.
• W2279131920 hasAuthorship W2279131920A5027021672 @default.
• W2279131920 hasAuthorship W2279131920A5027556665 @default.
• W2279131920 hasAuthorship W2279131920A5037610017 @default.
• W2279131920 hasAuthorship W2279131920A5039337111 @default.
• W2279131920 hasAuthorship W2279131920A5040081800 @default.
• W2279131920 hasAuthorship W2279131920A5048397234 @default.
• W2279131920 hasAuthorship W2279131920A5055743450 @default.
• W2279131920 hasAuthorship W2279131920A5067706688 @default.
• W2279131920 hasBestOaLocation W22791319201 @default.
• W2279131920 hasConcept C121608353 @default.
• W2279131920 hasConcept C126322002 @default.
• W2279131920 hasConcept C126894567 @default.
• W2279131920 hasConcept C141071460 @default.
• W2279131920 hasConcept C143998085 @default.
• W2279131920 hasConcept C184235292 @default.
• W2279131920 hasConcept C2777909004 @default.
• W2279131920 hasConcept C2778019345 @default.
• W2279131920 hasConcept C2778695046 @default.
• W2279131920 hasConcept C2781249067 @default.
• W2279131920 hasConcept C526805850 @default.
• W2279131920 hasConcept C57074206 @default.
• W2279131920 hasConcept C71924100 @default.
• W2279131920 hasConcept C72563966 @default.
• W2279131920 hasConcept C86803240 @default.
• W2279131920 hasConcept C95444343 @default.
• W2279131920 hasConceptScore W2279131920C121608353 @default.
• W2279131920 hasConceptScore W2279131920C126322002 @default.
• W2279131920 hasConceptScore W2279131920C126894567 @default.
• W2279131920 hasConceptScore W2279131920C141071460 @default.
• W2279131920 hasConceptScore W2279131920C143998085 @default.
• W2279131920 hasConceptScore W2279131920C184235292 @default.
• W2279131920 hasConceptScore W2279131920C2777909004 @default.
• W2279131920 hasConceptScore W2279131920C2778019345 @default.
• W2279131920 hasConceptScore W2279131920C2778695046 @default.
• W2279131920 hasConceptScore W2279131920C2781249067 @default.
• W2279131920 hasConceptScore W2279131920C526805850 @default.
• W2279131920 hasConceptScore W2279131920C57074206 @default.
• W2279131920 hasConceptScore W2279131920C71924100 @default.
• W2279131920 hasConceptScore W2279131920C72563966 @default.
• W2279131920 hasConceptScore W2279131920C86803240 @default.
• W2279131920 hasConceptScore W2279131920C95444343 @default.
• W2279131920 hasLocation W22791319201 @default.
• W2279131920 hasOpenAccess W2279131920 @default.
• W2279131920 hasPrimaryLocation W22791319201 @default.
• W2279131920 isParatext "false" @default.
• W2279131920 isRetracted "false" @default.
• W2279131920 magId "2279131920" @default.
• W2279131920 workType "article" @default.